IDO1 Protein (AA 1-407) (His tag)

Catalog No. ABIN1344081

Product Details

Target: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 1-407

Origin: Mouse

Source: Escherichia coli (E. coli)

Purification tag / Conjugate: This IDO1 protein is labelled with His tag.

Application: SDS-PAGE (SDS)

Purpose: IDO (mouse) (rec.) (His)

Cross-Reactivity: Mouse

Characteristics: Mouse IDO1 (aa 1-407) is fused at the C-terminus to a His-tag.

Purity: >90 % (SDS-PAGE)

Sterility: Sterile filtered

Endotoxin Level: <1EU/μg purified protein (LAL test).

Biological Activity Comment: Specific Activity: >100'000U/mg protein with L-tryptophan as substrate and after addition of 7μM hemin for protein induction. One unit is defined as the amount of enzyme that produces 1nmol of kynurenine per hour.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.2μm-filtered solution in 50 mM TRIS-Cl, pH 7.4, containing 1 mM EDTA.

Handling Advice: After opening, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles. For maximum product recovery after thawing, centrifuge the vial before opening the cap.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 2 years after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

Expiry Date: 24 months

Target Details

Target: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Alternative Name: IDO (IDO1 Products)

Background:

Indoleamine 2,3-dioxygenase 1, IDO, INDO

IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system's ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

Molecular Weight: ~40kDa (SDS-PAGE)

UniProt: P28776

Pathways: Activated T Cell Proliferation